Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
16 Leser
Artikel bewerten:
(0)

WayPoint Biomedical Holdings, Inc. CEO Discusses Recent Temporary Share Trading Suspension Resulting From July 2006 Unsolicited Stock Spamming


HUNTINGTON BEACH, Calif., March 13 /PRNewswire-FirstCall/ -- WayPoint Biomedical Holdings, Inc. CEO, Mr. Steven Fox, will address the temporary ten day suspension of their share trading by the SEC. The live Market News First IPTV show will allow Mr. Fox to tell WayPoint's side of the story related to the recent suspension. WayPoint has already contacted and stated their position to the SEC, where WayPoint denies any and all involvement with the July 2006 Stock spamming incident that is the alleged cause of the suspension.

During the show Mr. Fox will discuss WayPoint's Company position related to the suspension and time will be provided for viewer call-in questions directed toward Mr. Fox and WayPoint. Saul Albom and Steve Kanaval from Market News First will moderate the half hour show called "Inside The Trades," which will be held on March 13, 2007 at 4:00 PM Central time and can be viewed by going to http://www.mnl.com/ .

About WayPoint Biomedical Holdings, Inc.:

WayPoint Biomedical Holdings, Inc. , is a pioneering new biomedical technology firm, specializing in tests and devices for screening and monitoring human health, wellness, fitness and environment. The Company's develops and markets a unique array of cutting-edge products, which includes their Health Essist(R) Hangover-Free Topical Patch for the Convenience Store market and their OTC approved Health Essist Drugs-of-Abuse product range. WayPoint's tests offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Wellness & Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, two of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical and their product range visit http://www.waypointbiomedical.com/ , http://www.healthessist.com/ , http://www.drinkdetectiveusa.com/ .

Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Investor Relations: Steven Fox, 714-848-3200 E-mail: foxrsteven@aol.com

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.